IonStar could upend industry standards, and quicken medical diagnosis and drug development
A new protein analysis tool developed at the University at Buffalo could vastly increase the speed and precision with which disease and drug effects are analyzed.
The groundbreaking tool, called IonStar, is the first to provide near-perfect accuracy when quantifying and comparing the abundance of proteins in the bodies of people who are healthy and ill.
Compared to industry standard MaxQuant, IonStar improved the measurement consistency of proteins in low abundance and lowered the amount of missing data in results from 17 percent to 0.1 percent, a level that has never been achieved with large samples.
The new tool could increase the quality and accuracy of medical diagnosis and quicken the pace of pharmaceutical development.
“IonStar will totally change the face of clinical and pharmaceutical research and industry, where large investigations are often critical,” says Jun Qu, PhD, lead investigator and professor in the UB School of Pharmacy and Pharmaceutical Sciences.
The research was published yesterday in the Proceedings of the National Academy of Sciences (PNAS).
Playing spot the difference
The abundance of proteins in the body that correspond with disease or pharmaceutical reactions can provide researchers with vital clues for accurately diagnosing a condition, and for developing potential therapies and evaluating drug effects.
Protein analysis tools are used to quantify and compare the abundance of proteins in groups of healthy individuals with those who are ill or treated with a drug. Changes in protein abundances, when analyzed together, often reveal novel biomarkers.
The challenge for researchers is that current tools are not efficient at analyzing large numbers of samples. One type of method, the labeling-method, uses chemical tags to label proteins. The issue: The software can only analyze up to 10 samples at a time, making it difficult for researchers to conduct typical pharmaceutical and clinical studies, says Qu.
The alternative, the label-free method, can analyze a large number of samples at once at the expense of accuracy and precision, causing researchers to waste time and resources validating falsely identified biomarkers.
IonStar increases accuracy and precision and lowers missing data by improving on sample preparation methods, alignment and feature detection designs for mass spectrometry analysis.
“For example, in clinical trials, comparing a handful of patients gets you nowhere,” says Qu. “If you can analyze a large number of patients with high-quality data, you can discover and track biomarkers much more accurately and reliably. The same is true for pharmaceutical investigations.”
Proving the concept in traumatic brain injury
Researchers used IonStar to quantify proteins in rats with traumatic brain injury, a debilitating condition that accounts for 2.2 million emergency room visits annually in the United States.
Using 100 tissue samples, IonStar identified 7,000 proteins, including 1,000 that differed in abundance, without missing data.
IonStar also measured low-abundance proteins with higher accuracy and precision than other prevalent analysis tools. This capability is critical, says Qu, because proteins that appear in smaller amounts play a more influential role in the body.
“If higher-level proteins are soldiers, then lower-level proteins are the commanders. They are the regulators that tell the higher-level proteins what to do,” says Qu.
Qu has used IonStar and similar techniques to analyze protein variation in cancer, diabetes, cardiovascular disease, neurodegeneration and retina degeneration as well.
Future work on IonStar will focus on expanding the number of samples the tool can analyze.
The Latest on: Drug development
via Google News
The Latest on: Drug development
- Cincinnati Children’s inks deal with drug development firm on November 12, 2018 at 10:25 am
Cincinnati Children’s Hospital has entered into a research collaboration with California-based BridgeBio Pharma to identify and develop drugs to treat genetic diseases. “We are excited to launch this ... […]
- Optic Nerve Disorders Drug Development Pipeline Review, 2018 - ResearchAndMarkets.com on November 10, 2018 at 8:55 am
DUBLIN--(BUSINESS WIRE)--The "Optic Nerve Disorders Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the ... […]
- 2018 Drug Development Pipeline Review for Optic Nerve Disorders (Optic Neuropathy, Glaucoma, LHON and Optic Neuritis) on November 9, 2018 at 12:30 pm
The "Optic Nerve Disorders Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the pipeline landscape for disorders ... […]
- AI in drug development and personalized medicine on November 9, 2018 at 10:09 am
Medicine and other scientific areas have always used computing power wherever they could find it-- to help modeling go faster and arrive at viable drugs more quickly. But when we apply the most ... […]
- Pneumonia Drug Development market insights shared in detailed report on November 9, 2018 at 9:03 am
The Pneumonia Drug Development Market is expected to grow at a high rate by the year 2023. The businesses in Global Pneumonia Drug Development Market are coming up with innovative solutions in the for... […]
- Drug Price Controls that Threaten Research and Development on November 9, 2018 at 6:14 am
An administration proposal on prescription drugs prices could reduce the resources available for research and development of new drugs. The administration is proposing to link Medicare Part B reimburs... […]
- SAS boosts the analytics behind life-saving drug development on November 7, 2018 at 6:02 am
CARY, N.C., Nov. 7, 2018 /PRNewswire/ -- To conduct clinical trials and develop new therapeutics, health organizations must manage and analyze staggering amounts of data. For decades, SAS ® has been t... […]
- Amgen Picks Provention to Continue Development of Celiac Disease Drug on November 5, 2018 at 11:28 am
For the second time in three years, Amgen is turning to a smaller biotech to continue clinical development of an experimental celiac disease drug that was developed in its labs. Provention’s ... […]
- Global Transdermal Drug Delivery System Market Development and Trends Forecasts Report 2018-2023 on November 5, 2018 at 5:21 am
Global Transdermal Drug Delivery System Market Overview: Summary: Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication thr... […]
via Bing News